iLite® ADCC Target CD20 (+) Assay Ready Cells are designed to enable determination of the ADCC activity of existing or new anti-CD20 drug candidates.
iLite® ADCC Target CD20 (+) Assay Ready Cells are based on a human B lymphocyte cell line, Raji (ATCC# CCL-86), and have been genetically engineered and optimized to express high and constant levels of the surface antigen CD20.
The cells are to be use as target cells for measuring the ADCC activity of anti-CD20 antibodies and are optimized to give high sensitivity and specificity when used together with iLite ADCC Effector (V) Assay Ready Cells.
